# Tesamorelin vs Sermorelin: Structural and Pharmacologic Differences in the Literature > Tesamorelin vs sermorelin, compared from the literature: a stabilized full-length GHRH(1-44) analogue versus a truncated GHRH(1-29), and what that means for DPP-IV resistance and the studied evidence. Full-length versus truncated GHRH, the DPP-IV-resistance modification, and where the trial evidence actually sits for each. ## The short version Tesamorelin vs sermorelin comes down to length and stability. Both are GHRH analogues — lab copies of the brain's "make growth hormone" signal — but tesamorelin is the full 44-amino-acid chain with a chemical cap that protects it from being chopped up, while sermorelin is a shorter 29-amino-acid fragment. The practical difference for the literature: tesamorelin carries a deep, FDA-approved evidence base in HIV-associated fat, with crisp visceral- and liver-fat numbers. This page contrasts the two on structure and on what the studies on tesamorelin actually establish — without making efficacy claims about sermorelin's separate record. ## Structure: full-length GHRH(1-44) versus truncated GHRH(1-29) The core distinction in tesamorelin vs sermorelin is the molecule. Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone — the full-length GHRH(1-44) sequence — carrying a trans-3-hexenoic acid group on its N-terminus [4]. Sermorelin, by contrast, is the truncated GHRH(1-29): the first 29 amino acids, the shortest fragment that retains GHRH activity. The N-terminal modification is the functional headline. Native GHRH and its shorter fragments are cleaved within minutes by DPP-IV (the enzyme that inactivates the hormone). Tesamorelin's trans-3-hexenoic acid cap blocks that cleavage, conferring resistance and extending plasma activity relative to unmodified GHRH peptides [4]. Tesamorelin's empirical formula is C221H366N72O67S, molecular weight 5135.9 Da, supplied as the acetate salt — a larger, stabilized molecule than the truncated fragment. ## Pharmacology and the weight of evidence Both peptides share a mechanism: each binds the GHRH receptor on pituitary somatotrophs to stimulate pulsatile growth-hormone release, which raises IGF-1 [4]. Where they diverge sharply is the evidence base — and that is where this comparison can only speak to tesamorelin, because the cited literature here is tesamorelin's. Tesamorelin holds an FDA approval (NDA 022505, 2010) for HIV-associated lipodystrophy [5] and a clean trial deck: visceral fat -15.2% versus +5.0% placebo over 26 weeks [1], sustained at -18% over 52 weeks [2], IGF-1 +81.0% [1], and hepatic fat -37% relative in HIV NAFLD [6]. A 2026 meta-analysis of five trials pooled a -27.71 cm2 visceral-fat reduction [12]. Despite a terminal half-life of roughly 26-38 minutes, its downstream IGF-1 elevation is sustained across the dosing interval [15]. The point of [tesamorelin vs sermorelin](/vs-sermorelin) here is structural and definitional — full-length stabilized analogue versus truncated fragment — not a head-to-head efficacy claim, which the cited record does not support. ## How deep the tesamorelin clinical program runs The evidence distinction worth naming is depth. Tesamorelin's effects were not inferred from the mechanism alone; they were measured in a clinical program unusually large for a GHRH analogue. That program includes two pivotal Phase 3 randomized trials in HIV-associated lipodystrophy [1][2], a JAMA trial of visceral and liver fat [3], a Lancet HIV trial in fatty liver disease [6], a dedicated type-2-diabetes safety trial, a 2024 trial in the integrase-inhibitor era [10], and a 2026 meta-analysis pooling five trials [12]. That is the basis for tesamorelin's FDA approval and for the precise figures this site cites — visceral fat -15.2% [1], IGF-1 +81.0% [1], hepatic fat -37% relative [6]. A structural comparison can place tesamorelin's full-length, DPP-IV-resistant design beside sermorelin's truncated fragment [4], but the quantified outcomes here belong to tesamorelin's trials specifically. This page does not assign comparable numbers to any other GHRH analogue, because the cited record does not contain them. ## What the DPP-IV-resistance difference means in practice The single design choice that separates the two molecules — the N-terminal cap — has a concrete pharmacologic consequence. DPP-IV (dipeptidyl peptidase-IV) is the protease that clips native GHRH and its short fragments within minutes of release. Tesamorelin's trans-3-hexenoic acid group sits at exactly the bond DPP-IV would attack, blocking it [4]. A truncated GHRH(1-29) fragment without that modification has no such guard at the cleavage site. The practical reading is that tesamorelin was engineered for stability, and its activity was then characterized in a deep clinical program. Even so, tesamorelin's own plasma exposure remains short — apparent clearance about 1,060 L/h, terminal half-life roughly 26-38 minutes per secondary sources [15] — which underscores that the design goal was resistance to immediate enzymatic destruction, not a long circulating life. What carries the once-daily effect is the sustained downstream IGF-1 signal, not a long-lived peptide [15]. This is a structural and pharmacologic contrast, not a claim that one peptide outperforms the other in any head-to-head human trial, which the cited record does not contain. ## What this comparison cannot claim A clean structural contrast is not a clinical verdict. The cited literature on this site documents tesamorelin — its receptor mechanism, its HIV-lipodystrophy approval, and its visceral- and liver-fat trial outcomes [1][2][5][6]. It does not contain a randomized head-to-head trial of tesamorelin against sermorelin, so this page makes no claim that either is more effective, safer, or better tolerated than the other in people. What can be said precisely is the structural fact: tesamorelin is a stabilized full-length GHRH(1-44) analogue with a DPP-IV-resistant N-terminal modification and an FDA approval for one narrow indication, while sermorelin is the truncated GHRH(1-29) fragment [4][5]. Tesamorelin's approval extends only to HIV-associated lipodystrophy; every other use is off-label and investigational, and that boundary applies regardless of how it is compared to any other GHRH analogue [5]. --- A clear-light reading of the tesamorelin record — every trial figure logged at the snow-line where the approved HIV-lipodystrophy use ends and the off-label questions begin; a luminous reference plate, not a clinic, a pharmacy, or a prescription.